Cargando…

Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever

Lassa fever (LF) causes multisystem disease and has a fatality rate <70%. Severe cases exhibit abnormal coagulation, endothelial barrier disruption, and dysfunctional platelet aggregation but the underlying mechanisms remain poorly understood. In Sierra Leone during 2015–2018, we assessed LF pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horton, Lucy E., Cross, Robert W., Hartnett, Jessica N., Engel, Emily J., Sakabe, Saori, Goba, Augustine, Momoh, Mambu, Sandi, John Demby, Geisbert, Thomas W., Garry, Robert F., Schieffelin, John S., Grant, Donald S., Sullivan, Brian M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588510/ https://www.ncbi.nlm.nih.gov/pubmed/33079033 http://dx.doi.org/10.3201/eid2611.191694

Ejemplares similares

Lassa Fever among Children in Eastern Province, Sierra Leone: A 7-year Retrospective Analysis (2012–2018)
por: Samuels, Robert J., et al.
Publicado: (2021)

Data set on Lassa fever in post-conflict Sierra Leone
por: Shaffer, Jeffrey G., et al.
Publicado: (2019)

High crossreactivity of human T cell responses between Lassa virus lineages
por: Sullivan, Brian M., et al.
Publicado: (2020)

Identification of Common CD8(+) T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone
por: Sakabe, Saori, et al.
Publicado: (2020)

Novel Tools for Lassa Virus Surveillance in Peri-domestic Rodents
por: Smither, Allison R., et al.
Publicado: (2023)

Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019
por: Shaffer, Jeffrey G., et al.
Publicado: (2021)

Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses
por: Gunn, Bronwyn M, et al.
Publicado: (2020)

Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever
por: Boisen, Matthew L., et al.
Publicado: (2018)

A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges
por: Shaffer, Jeffrey G., et al.
Publicado: (2019)

Expansion of CD8(+) T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors
por: LaVergne, Stephanie M., et al.
Publicado: (2022)

Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection
por: Branco, Luis M, et al.
Publicado: (2011)

Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects
por: Branco, Luis M, et al.
Publicado: (2010)

Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages
por: Heinrich, Megan L., et al.
Publicado: (2020)

Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades
por: Klitting, Raphaëlle, et al.
Publicado: (2022)

Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak
por: Boisen, Matthew L., et al.
Publicado: (2020)

A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)–Study protocol
por: Penfold, Suzanne, et al.
Publicado: (2023)

Lassa fever-induced hearing loss: The neglected disability of hemorrhagic fever
por: Ficenec, Samuel C., et al.
Publicado: (2020)

Lassa Fever in Post-Conflict Sierra Leone
por: Shaffer, Jeffrey G., et al.
Publicado: (2014)

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits
por: Robinson, James E., et al.
Publicado: (2016)

Elevated l-threonine is a biomarker for Lassa fever and Ebola
por: Gale, Trevor V., et al.
Publicado: (2020)

Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study
por: Grant, Donald S., et al.
Publicado: (2023)

965. Applying Clinical Prediction Tools to Patients with Lassa Fever
por: Chiosi, John, et al.
Publicado: (2018)

729. Lassa Fever Associated Hearing Loss
por: Ficenec, Samuel, et al.
Publicado: (2021)

Ribavirin for Lassa Fever Postexposure Prophylaxis
por: Hadi, Christiane M., et al.
Publicado: (2010)

Pathogenesis of lassa fever in cynomolgus macaques
por: Hensley, Lisa E, et al.
Publicado: (2011)

Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance
por: Branco, Luis M, et al.
Publicado: (2008)

Lassa fever — the road ahead
por: Garry, Robert F.
Publicado: (2022)

A Review of Hearing Loss Associated with Zika, Ebola, and Lassa Fever
por: Ficenec, Samuel C., et al.
Publicado: (2019)

A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus
por: Cross, Robert W., et al.
Publicado: (2023)

Ophthalmic manifestations and vision impairment in Lassa fever survivors
por: Li, Alexa L., et al.
Publicado: (2020)

Using Modelling to Disentangle the Relative Contributions of Zoonotic and Anthroponotic Transmission: The Case of Lassa Fever
por: Lo Iacono, Giovanni, et al.
Publicado: (2015)

Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses
por: Marzi, Andrea, et al.
Publicado: (2015)

Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time
por: Barnes, Kayla G., et al.
Publicado: (2020)

Health seeking behavior after the 2013–16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone
por: Koch, Mikaela R., et al.
Publicado: (2021)

Insights into Endotheliopathy in COVID-19
por: Filbin, Michael R.
Publicado: (2022)

Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers
por: Gale, Trevor V., et al.
Publicado: (2017)

Iatrogenic air embolism: pathoanatomy, thromboinflammation, endotheliopathy, and therapies
por: Marsh, Phillip L., et al.
Publicado: (2023)

Development of a New Vaccine for the Prevention of Lassa Fever
por: Geisbert, Thomas W, et al.
Publicado: (2005)

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation
por: Gu, Sean X., et al.
Publicado: (2020)

Circulating Markers of Angiogenesis and Endotheliopathy in COVID-19
por: Meizlish, Matthew L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_19dvjgcl7ibf5a1u3mb5dmrf0i